ArticleHardwareX2024
A do-it-yourself benchtop device for highly scalable flow synthesis of protein-based nanoparticles.
Article in HardwareX, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthesis of nanoparticles is typically carried out in batch procedures, which offer limited control of parameters, and a narrow range of possible batch volumes. In contrast, flow synthesis systems, usually having a microfluidic chip as a crucial part, are devoid of these drawbacks. However, large scale devices - millifluidic systems - may offer several advantages over microfluidic systems, such as easier and cheaper production, enhanced throughput, and reduced channel clogging. Here we report a millifluidic system for the generation of protein nanoparticles, using the flow format of the original swift thermal formation technology (STF), which can process batch volume ranging from 100 µl to any practically significant amount. Capabilities of the system are demonstrated with model synthesis of Epirubicin-encapsulated BSA nanoparticles. A better degree of scalability of the synthesis over batch procedure is shown: with a 10-fold working volume increase, hydrodynamic diameter and loading capacity changed by only 10 % and 1 % respectively, compared to 60 % and 30 % for the batch synthesis. Additionally, we provide all engineering drawings, electrical circuits, programming code and nuances of assembly and operation, so that our findings can be easily reproduced. The ease of construction of the device and the superior characteristics of the resulting nanoparticles compared to the batch method indicate application potential in both the biomedical research and industrial spheres.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.